Welcome to our dedicated page for Atea Pharmaceuticals news (Ticker: AVIR), a resource for investors and traders seeking the latest updates and insights on Atea Pharmaceuticals stock.
Atea Pharmaceuticals develops oral antiviral therapeutics for serious viral diseases. The company uses a proprietary nucleos(t)ide prodrug platform focused on single-stranded RNA viruses and is building a pipeline that includes bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for hepatitis C virus treatment.
Recurring Atea news covers clinical and preclinical antiviral development, including HCV Phase 3 studies such as C-BEYOND and C-FORWARD, hepatitis E virus candidates including AT-587 and AT-2490, scientific conference presentations, financial results, and business updates tied to pipeline execution.
Atea Pharmaceuticals (Nasdaq: AVIR) reported Q4 and full-year 2025 results and a business update. The company completed enrollment in C-BEYOND (>880 patients) and expects C-BEYOND topline results mid-2026 and C-FORWARD results around year-end 2026 for the bemnifosbuvir/ruzasvir HCV regimen.
Cash and investments were $301.8M at 12/31/2025; AT-587 for hepatitis E is expected to enter clinical development mid-2026.
Atea Pharmaceuticals (Nasdaq: AVIR) will host a live conference call and audio webcast on Thursday, March 5, 2026 at 4:30 p.m. ET to report fourth quarter and full year results for the period ended December 31, 2025, and to provide a business update.
Participants may register for the call, join via telephone using conference ID 10206566, or listen on the company's Investor Relations website at ir.ateapharma.com. An archive of the webcast will be posted about two hours after the call and remain available for at least 90 days.
Atea Pharmaceuticals (Nasdaq: AVIR) presented preclinical data at CROI 2026 showing AT-587 and AT-2490 are potent in vitro inhibitors of hepatitis E virus (HEV), with AT-587 selected as the lead candidate. AT-587 and AT-2490 were 30–150-fold more potent versus sofosbuvir and ribavirin and produced high levels of active metabolite in human liver cells with no observed toxicity. Atea plans to initiate a Phase 1 clinical program mid-2026. Poster: 596; CROI Feb 22–25, 2026.
Atea Pharmaceuticals (NASDAQ: AVIR) will present 2026 strategic priorities at the 44th Annual J.P. Morgan Healthcare Conference and provided program and pipeline updates on Jan 8, 2026. The company reported $301.8 million cash and investments at Dec 31, 2025, with a cash runway expected through 2027. Atea is advancing a global Phase 3 program for a fixed-dose combination of bemnifosbuvir and ruzasvir for HCV: C-BEYOND (North America) is fully enrolled with >880 patients and topline results are expected mid-2026; C-FORWARD (outside North America) expects enrollment completion mid-2026 and topline results around year-end 2026. Phase 2 data showed 98% SVR12 (per-protocol) for an 8-week regimen. Atea selected AT-587 for HEV and anticipates initiating a Phase 1 study mid-2026.
Atea Pharmaceuticals (Nasdaq: AVIR) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026 at 7:30 a.m. PT in San Francisco.
Jean-Pierre Sommadossi, PhD, CEO and founder, and other Atea management will present. A live webcast will be available on the company's investor site at https://ir.ateapharma.com, with an archived webcast available for at least 90 days after the event.
Atea Pharmaceuticals (Nasdaq: AVIR) completed enrollment of more than 880 treatment‑naïve patients in the North American C‑BEYOND Phase 3 trial evaluating a fixed‑dose combination of bemnifosbuvir and ruzasvir versus the comparator fixed‑dose sofosbuvir and velpatasvir regimen.
C‑BEYOND enrolled at ~120 sites in the US and Canada and topline results are expected mid‑2026. Atea is also advancing C‑FORWARD, a parallel Phase 3 outside North America targeting ~880 patients at ~120 sites, with enrollment expected mid‑2026 and topline results anticipated year‑end 2026. The bemnifosbuvir/ruzasvir regimen is oral once‑daily for 8 weeks (non‑cirrhotic) or 12 weeks (compensated cirrhosis), while the comparator is 12 weeks.
ReAlta Life Sciences (AVIR) appointed Howard Berman, Ph.D. as Executive Chairman effective immediately on November 25, 2025. The company said Dr. Berman brings more than 20 years of biopharma leadership across company formation, clinical development, strategic partnerships, and public-market execution.
ReAlta highlighted pegtarazimod's clinical data and safety profile across three life-threatening diseases and said the peptide platform targets complement and neutrophil-driven inflammation. Dr. Berman currently chairs Coya Therapeutics and serves on the board of Atea Pharmaceuticals.
Atea Pharmaceuticals (Nasdaq: AVIR) announced that CEO and founder Jean-Pierre Sommadossi, PhD, alongside other management team members, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025 at 10:00 a.m. ET in Coral Gables, FL.
A live webcast will be available on the company website at https://ir.ateapharma.com, with an archived webcast accessible for at least 90 days following the event.
Atea Pharmaceuticals (Nasdaq: AVIR) reported Q3 2025 results and a business update highlighting progress in its global HCV Phase 3 program, new AASLD data, and a new HEV development program.
Key points: C-BEYOND expected fully enrolled by end-2025 with topline mid-2026; C-FORWARD enrollment expected complete mid-2026 with topline around end-2026. New data at AASLD support a dual mechanism for bemnifosbuvir and high bioavailability of the bemnifosbuvir/ruzasvir FDC, including dosing with famotidine. Two HEV leads (AT-587, AT-2490) are in IND-enabling studies with Phase 1 anticipated mid-2026.
Financials: $329.3M cash and marketable securities (Sept 30, 2025); Q3 R&D $38.3M, G&A $7.2M; Q3 net loss $42.0M or $0.53 per share. The company completed a $25M repurchase (7,673,793 shares), leaving 78,126,796 shares outstanding.
Atea Pharmaceuticals (Nasdaq: AVIR) presented new data at The Liver Meeting 2025 supporting its fixed-dose combination of bemnifosbuvir (BEM) and ruzasvir (RZR) as a potential best-in-class, short-duration HCV regimen. Key findings include a modeled time to cure of ~7–8 weeks, Phase 2 SVR12 of 98% in the per-protocol population and 95% regardless of adherence, a resistance analysis showing a high barrier to resistance, and Phase 1 data showing the FDC has high relative bioavailability and can be dosed with or without food or with famotidine. The commercial FDC is being used in the ongoing Phase 3 program. A virtual KOL investor panel is scheduled for Nov 13, 2025 at 10:00 AM ET.